Viridian Therapeutics Reports Topline Data from P-III (THRIVE-2) Study of Veligrotug to Treat Chronic Thyroid Eye Disease
Shots:
- The P-III (THRIVE-2) study assessed veligrotug (IV) vs PBO in patients (n=188) with chronic thyroid eye disease (TED), with a mean TED duration of 69.8mos.
- Study achieved 1 & 2EPs, showing proptosis responder rate (PRR) of 56% vs 8%, with a mean reduction of 2.34mm vs 0.46mm; diplopia response rate of 56% vs 25%, with 32% vs 14% complete resolution; CAS reduction to 0/1 in 54% vs 24%, with 2.9 vs 1.3-point mean reduction & ORR of 56% vs 7%
- Veligrotug's BLA submission is planned in H2’25. In addition, Viridian is dosing patients in P-III (REVEAL-1 & REVEAL-2) trials of VRDN-003 in active and chronic TED, with topline data expected in H1’26 and BLA submission by YE’26
Ref: Viridian Therapeutics | Image: Viridian Therapeutics
Related News:- AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
